Literature DB >> 16829651

Magnetic resonance as a cancer imaging biomarker.

A Gregory Sorensen1.   

Abstract

Cancer is a diverse disease with many manifestations. Magnetic resonance (MR) has a wide range of sensitivities, and therefore has often been used to study cancer in humans in numerous different ways, most typically with MR spectroscopy and MR imaging. This article is not an exhaustive catalog of the use of MR in cancer, but will briefly highlight some of the many promising MR methods that have been developed, proposed, or used to focus on the problem of detecting and characterizing cancer, its treatments, and adverse effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829651     DOI: 10.1200/JCO.2006.06.6597

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

1.  Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.

Authors:  Albert E Cerussi; Vaya W Tanamai; David Hsiang; John Butler; Rita S Mehta; Bruce J Tromberg
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

Review 2.  Magnetic resonance imaging methodology.

Authors:  Ewald Moser; Andreas Stadlbauer; Christian Windischberger; Harald H Quick; Mark E Ladd
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

3.  Repeatability of dynamic contrast enhanced vp parameter in healthy subjects and patients with brain tumors.

Authors:  Moran Artzi; Gilad Liberman; Deborah T Blumenthal; Felix Bokstein; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

Review 4.  PET/MRI for neurologic applications.

Authors:  Ciprian Catana; Alexander Drzezga; Wolf-Dieter Heiss; Bruce R Rosen
Journal:  J Nucl Med       Date:  2012-11-09       Impact factor: 10.057

Review 5.  Listening for the therapeutic window: Advances in drug delivery utilizing photoacoustic imaging.

Authors:  Colman Moore; Fang Chen; Junxin Wang; Jesse V Jokerst
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

6.  Simultaneous QSM and metabolic imaging of the brain using SPICE.

Authors:  Xi Peng; Fan Lam; Yudu Li; Bryan Clifford; Zhi-Pei Liang
Journal:  Magn Reson Med       Date:  2017-10-24       Impact factor: 4.668

Review 7.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Authors:  Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Journal:  BMC Cancer       Date:  2009-12-16       Impact factor: 4.430

8.  Applications of the repeatability of quantitative imaging biomarkers: a review of statistical analysis of repeat data sets.

Authors:  Huiman X Barnhart; Daniel P Barboriak
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

9.  Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response.

Authors:  R Venkatasubramanian; R B Arenas; M A Henson; N S Forbes
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 10.  Biomarkers of response and resistance to antiangiogenic therapy.

Authors:  Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.